Cycle Pharma
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
The Broers Building 21 Jj Thomson Ave, C...Phone Number
+44 1223354118Website
www.cyclepharma.comRevenue
$33.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Cycle Pharma
Cycle Pharmaceuticals is a UK-based pharmaceutical company focused on developing and commercializing treatments for patients with rare diseases, particularly in neurological, metabolic, and immunological areas. The company emphasizes improving existing therapies, repurposing drugs, and developing new formulations to enhance patient outcomes. With operations in both the UK and the United States, Cycle Pharmaceuticals provides not only medications but also patient support services, including nutritional guidance and assistance programs. The company aims to address unmet medical needs and improve quality of life for patients and caregivers dealing with rare and often genetic conditions.Explore more
Cycle Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cycle Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cycle Pharma launches new products
Funding: Get notified immidiatlly once Cycle Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cycle Pharma
Click to see if Cycle Pharma had a recent Job posting/layoffs
Cycle Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Cycle Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Cycle Pharma recently announced quarterly report
Check if Cycle Pharma has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Cycle Pharma
Find 3 more new buyers
Compare Similar Companies to Cycle Pharma
Compare insights from companies similar to Cycle Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cycle Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cycle Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cycle Pharma.
Cycle Pharma financials insights
Gather financial insights about Cycle Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$25M
Cycle Pharma Tech Stack
A closer look at the technologies used by Cycle Pharma
Most Recent Scoops
Hiring Plans
Cycle Pharma has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Open Position
Hiring Plans
Hiring Plans
Cycle Pharma News & Media
Cycle Pharmaceuticals Selects LeMed Specialty Pharmacy as Exclusive U.S. Specialty Pharmacy Distribution and Services Partner for HARLIKU™ (nitisinone) Tablets --the First and only FDA-approved Treatment for Reducing Urinary Homogentisic Acid (HGA) in Adult Patients with Alkaptonuria (AKU)
Proven rare-disease expertise, industry-leading patient satisfaction, and 20-plus years of truly independent specialty-pharmacy service set LeMed apart. BRONX, N.Y., July 21, 2025 /PRNewswire/ -- Cycle Pharmaceuticals today announced they have awarded LeMed Specialty Pharmacy the...Cycle Pharma Acquires Banner Life Sciences, LLC
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals, Inc. (Cycle) announces today completion of the acquisition of Banner Life Sciences, LLC (Banner) which includes its BAFIERTAM® (monomethyl fumarate) product for the treatment of relapsing forms of multiple sclerosis (MS), in adults, approved by the US Food and Drug Administration (FDA). MS affects an estimated 1 million people in the US with around 200 new cases being diagnosed each week.1 Approximately 85% of diagnoses are thOrsini Now a Specialty Pharmacy Provider for SAJAZIR™ (icatibant) Injection, to Treat Acute HAE Attacks
ELK GROVE VILLAGE, Ill., Nov. 5, 2024 /PRNewswire/ -- Orsini has been chosen by Cycle Pharmaceuticals to distribute SAJAZIR™ (icatibant) Injection, a subcutaneous treatment for acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. SAJAZIR is the ninth HAE...Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (“Cycle”), a dynamic leader in developing rare disease therapies, today reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) for an all-cash consideration of $8.00 per Vanda share. Cycle is making its renewed proposal public for the benefit of Vanda shareholders in light of the Vanda Board’s continued refusal to engage following the receipt of mu
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cycle Pharma
Sign Up For FreeTo access detailed company insights
Cycle Pharmaceuticals is a UK-based pharmaceutical company focused on developing and commercializing treatments for patients with rare diseases, particularly in neurological, metabolic, and immunological areas. The company emphasizes improving existing therapies, repurposing drugs, and developing new formulations to enhance patient outcomes. With o... Read More
